5Wang H, Chen M, Ni Y, et al. Antimierobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003-2008. Int J Antimicrob Agents, 2010, 35..227- 234.
6Adams MD, Nickel GC, Bajaksouzian S, et al. Resistance to olistin in Acinetobacter baumannii associated with mutations in Lhe PmrAB two-component system. Antimicrob Agents Chemother, .009, 53:3628-3634.
7Gordon NC, Wareham DW. A review of clinical and microbiological outcomes following treatment of infections involving muhidrug-resistant Acinetobacter baumannii with tigecycline. J Antimicrob Chemother, 2009, 63:775-780.
9Tam VH, Gamez EA, Weston JS, et al. Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint. Clin Infect Dis, 2008, 46:862-867.
10Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of earbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Autimicrob Agents Chemother, 2008, 52 : 1028-1033.
